Literature DB >> 19254810

The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids.

Gregory A Hawkins1, Ross Lazarus, Richard S Smith, Kelan G Tantisira, Deborah A Meyers, Stephen P Peters, Scott T Weiss, Eugene R Bleecker.   

Abstract

BACKGROUND: Corticosteroids exert their anti-inflammatory action by binding and activating the intracellular glucocorticoid receptor heterocomplex.
OBJECTIVE: We sought to evaluate the genes HSPCB, HSPCA, STIP1, HSPA8, DNAJB1, PTGES3, FKBP5, and FKBP4 on corticosteroid response.
METHODS: White asthmatic subjects (n = 382) randomized to once-daily flunisolide or conventional inhaled corticosteroid therapy were genotyped. Outcome measures were baseline FEV1, percent predicted FEV1, and percent change in FEV1 after corticosteroid treatment. Multivariable analyses adjusted for age, sex, and height were performed, fitting the most appropriate genetic model based on the quantitative mean derived from ANOVA models to determine whether there was an independent effect of polymorphisms on change in FEV1 independent of baseline level.
RESULTS: Positive recessive model correlations for STIP1 single nucleotide polymorphisms were observed for baseline FEV1 (rs4980524, P = .009; rs6591838, P = .0045; rs2236647, P = .002; and rs2236648; P = .013), baseline percent predicted FEV1 (rs4980524, P = .002; rs6591838, P = .017; rs2236647, P = .003; and rs2236648, P = .008), and percent change in FEV1 at 4 weeks (rs4980524, P = .044; rs6591838, P = .016; and rs2236647, P = .01) and 8 weeks (rs4980524, P = .044; rs6591838, P = .016; and rs2236647; P = .01) or therapy. Haplotypic associations were observed for baseline FEV1 and percent change in FEV1 at 4 weeks of therapy (P = .05 and P = .01, respectively). Significant trends toward association were observed for baseline percent predicted FEV1 and percent change in FEV1 at 8 weeks of therapy. Positive correlations between haplotypes and percent change in FEV1 were also observed.
CONCLUSIONS: STIP1 genetic variations might play a role in regulating corticosteroid response in asthmatic subjects with reduced lung function. Replication in a second asthmatic population is required to confirm these observations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254810      PMCID: PMC4317788          DOI: 10.1016/j.jaci.2009.01.049

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  32 in total

Review 1.  Severe asthma: epidemiology, pathophysiology and treatment.

Authors:  Sally Wenzel
Journal:  Mt Sinai J Med       Date:  2003-05

Review 2.  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Authors:  William B Pratt; David O Toft
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

3.  Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.

Authors:  Aaron Deykin; Michael E Wechsler; Homer A Boushey; Vernon M Chinchilli; Susan J Kunselman; Timothy J Craig; Emily DiMango; John V Fahy; Monica Kraft; Frank Leone; Stephen C Lazarus; Robert F Lemanske; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

4.  Ligand binding by TPR domains.

Authors:  Aitziber L Cortajarena; Lynne Regan
Journal:  Protein Sci       Date:  2006-05       Impact factor: 6.725

Review 5.  Corticosteroids: the drugs to beat.

Authors:  Peter J Barnes
Journal:  Eur J Pharmacol       Date:  2006-01-24       Impact factor: 4.432

6.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

7.  Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance.

Authors:  J W Koper; R P Stolk; P de Lange; N A Huizenga; G J Molijn; H A Pols; D E Grobbee; M Karl; F H de Jong; A O Brinkmann; S W Lamberts
Journal:  Hum Genet       Date:  1997-05       Impact factor: 4.132

8.  The role of DnaJ-like proteins in glucocorticoid receptor.hsp90 heterocomplex assembly by the reconstituted hsp90.p60.hsp70 foldosome complex.

Authors:  K D Dittmar; M Banach; M D Galigniana; W B Pratt
Journal:  J Biol Chem       Date:  1998-03-27       Impact factor: 5.157

Review 9.  Chaperoning of glucocorticoid receptors.

Authors:  W B Pratt; Y Morishima; M Murphy; M Harrell
Journal:  Handb Exp Pharmacol       Date:  2006

10.  Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene.

Authors:  M Karl; S W Lamberts; S D Detera-Wadleigh; I J Encio; C A Stratakis; D M Hurley; D Accili; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

View more
  42 in total

1.  Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus.

Authors:  Kelan G Tantisira; Amy Damask; Stanley J Szefler; Brooke Schuemann; Amy Markezich; Jessica Su; Barbara Klanderman; Jody Sylvia; Rongling Wu; Fernando Martinez; Homer A Boushey; Vernon M Chinchilli; Dave Mauger; Scott T Weiss; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2012-04-26       Impact factor: 21.405

Review 2.  Update in asthma 2009.

Authors:  Wendy C Moore; Rodolfo M Pascual
Journal:  Am J Respir Crit Care Med       Date:  2010-06-01       Impact factor: 21.405

3.  Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity.

Authors:  Joseph C Maranville; Shaneen S Baxter; David B Witonsky; Meredith A Chase; Anna Di Rienzo
Journal:  Am J Hum Genet       Date:  2013-09-19       Impact factor: 11.025

Review 4.  Asthma Pharmacogenomics: 2015 Update.

Authors:  Joshua S Davis; Scott T Weiss; Kelan G Tantisira
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

5.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

Review 6.  The pharmacogenetics and pharmacogenomics of asthma therapy.

Authors:  S M Tse; K Tantisira; S T Weiss
Journal:  Pharmacogenomics J       Date:  2011-10-11       Impact factor: 3.550

Review 7.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 8.  Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine.

Authors:  Victor E Ortega; Deborah A Meyers
Journal:  J Allergy Clin Immunol       Date:  2014-01       Impact factor: 10.793

Review 9.  Integrative systems biology approaches in asthma pharmacogenomics.

Authors:  Amber Dahlin; Kelan G Tantisira
Journal:  Pharmacogenomics       Date:  2012-09       Impact factor: 2.533

Review 10.  Personalised medicine and asthma diagnostics/management.

Authors:  Samuel J Wadsworth; Andrew J Sandford
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.